share_log

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470

Benzinga ·  Feb 13 05:34

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $470.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment